Good Lifestyle

Swiss Company Nestlé, better known as Kat, Nescafe kit manufacturers and a lean cuisine, is looking for us to get rid of food allergies, starting with the fered allergy of the peanut.The food producer has acquired Aimmune Therapeutics, a California-based bio-pharmaceutical company, which has developed a revolutionary peanut allergy treatment.

In an agreement of $ 2 billion, Nestlé will take full property of Palforzia, a treatment for peanut allergies in children and adolescents aged 4 to 17 who hasreceived the Food and Drug Administration of the United States (FDA) approval earlier this year. The drug is supposed to desensitize allergies to peanut protein, which should reduce the severity and frequency of allergic reactions.

The acquisition is part of the prosecution of the food giant in the field of nutritional therapy, for which they formed the Nestlé Science Division (NHS) in 2011. In 2016, NHS also invested in the development of a Test of dairy allergies. By acquiring Aimmune, NHS will now have options for prevention, diagnosis and medical treatment available for one of the world's most common food allergies,According to NHS head, Greg Bear.

Leave it to the world's largest catering and beverage company to solve a problem by placing around 240 million people worldwide. According to Behar, the company has "the technology platform for other food allergies in development" and would beWork on treatment for eggs and other black allergies following.

Due to the CVIV-19 pandemic, the highly anticipated launch of Palforzia has not started the ground yet, but the acquisition contract is certain to move things in 2021. The Company occupies an exclusivity of 12 years on their patent, which will prevent generic versions from the drug from entering the duration market.

do not forget toSubscribe to our newsletterTo get the latest news from the restaurant delivered directly to your inbox.